SG11201807991QA - Use of nucleosome-transcription factor complexes for cancer detection - Google Patents
Use of nucleosome-transcription factor complexes for cancer detectionInfo
- Publication number
- SG11201807991QA SG11201807991QA SG11201807991QA SG11201807991QA SG11201807991QA SG 11201807991Q A SG11201807991Q A SG 11201807991QA SG 11201807991Q A SG11201807991Q A SG 11201807991QA SG 11201807991Q A SG11201807991Q A SG 11201807991QA SG 11201807991Q A SG11201807991Q A SG 11201807991QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cancer
- transcription factor
- nucleosome
- phocas
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1604806.8A GB201604806D0 (en) | 2016-03-22 | 2016-03-22 | Method of identifying a cancer of unknown origin |
| PCT/EP2017/056851 WO2017162755A1 (en) | 2016-03-22 | 2017-03-22 | Use of nucleosome-transcription factor complexes for cancer detection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807991QA true SG11201807991QA (en) | 2018-10-30 |
Family
ID=55968658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807991QA SG11201807991QA (en) | 2016-03-22 | 2017-03-22 | Use of nucleosome-transcription factor complexes for cancer detection |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200363418A1 (https=) |
| EP (3) | EP3433616B2 (https=) |
| JP (1) | JP6777757B2 (https=) |
| KR (2) | KR102246699B1 (https=) |
| CN (1) | CN109313192B (https=) |
| AU (1) | AU2017238442A1 (https=) |
| CA (1) | CA3018428C (https=) |
| ES (2) | ES2861440T5 (https=) |
| GB (1) | GB201604806D0 (https=) |
| MY (1) | MY187655A (https=) |
| SG (1) | SG11201807991QA (https=) |
| WO (1) | WO2017162755A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202238131A (zh) | 2020-11-25 | 2022-10-01 | 比利時商比利時意志有限公司 | 測量無細胞核蛋白染色質片段之方法 |
| TW202242130A (zh) * | 2020-12-29 | 2022-11-01 | 比利時商比利時意志有限公司 | 循環轉錄因子分析 |
| TW202242145A (zh) | 2020-12-29 | 2022-11-01 | 比利時商比利時意志有限公司 | 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析 |
| US20240318259A1 (en) * | 2021-09-24 | 2024-09-26 | Oncocross Co., Ltd. | Method for determining primary tumor site |
| WO2025073909A1 (en) | 2023-10-04 | 2025-04-10 | Belgian Volition Srl | Pcr method for detecting ctcf occupied cfdna fragments |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001249548A1 (en) * | 2000-03-27 | 2001-10-08 | Thomas Jefferson University | Compositions and methods for identifying and targeting cancer cells |
| ES2399110T3 (es) * | 2001-09-14 | 2013-03-25 | F. Hoffmann-La Roche Ag | Diagnóstico diferencial de los trastornos del metabolismo del hierro por medio de cuatro parámetros independientes y recomendaciones para el tratamiento de estos trastornos del metabolismo del hierro |
| US7248921B2 (en) * | 2003-06-02 | 2007-07-24 | Cameron Health, Inc. | Method and devices for performing cardiac waveform appraisal |
| US20040018525A1 (en) * | 2002-05-21 | 2004-01-29 | Bayer Aktiengesellschaft | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma |
| US20040236188A1 (en) * | 2003-05-19 | 2004-11-25 | Ge Medical Systems Information | Method and apparatus for monitoring using a mathematical model |
| US8029989B2 (en) * | 2005-08-26 | 2011-10-04 | The Trustees Of The University Of Pennsylvania | Method using snail transcriptional repressor |
| US20090298097A1 (en) * | 2007-07-17 | 2009-12-03 | Harris Pamela J | Methods for the diagnosis of lung cancer |
| JP4873510B2 (ja) * | 2008-07-01 | 2012-02-08 | 学校法人日本大学 | 標的遺伝子特異的ヒストン修飾制御剤 |
| MY148542A (en) * | 2009-06-15 | 2013-04-30 | Cancer Res Initiatives Foundation | A method for the assessment of cancer in a biological sample obtained from a subject |
| EP2270510A1 (en) * | 2009-07-02 | 2011-01-05 | EMBL (European Molecular Biology Laboratory) | Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms |
| GB201115098D0 (en) * | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
| GB201115095D0 (en) * | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
| CN104067125B (zh) * | 2011-12-07 | 2017-12-26 | 比利时意志有限责任公司 | 用于检测核小体加合物的方法 |
| GB201303576D0 (en) | 2013-02-28 | 2013-04-10 | Singapore Volition Pte Ltd | Method for predicting therapy efficacy using nucleosome structure biomarkers |
-
2016
- 2016-03-22 GB GBGB1604806.8A patent/GB201604806D0/en not_active Ceased
-
2017
- 2017-03-22 CA CA3018428A patent/CA3018428C/en active Active
- 2017-03-22 EP EP17712782.6A patent/EP3433616B2/en active Active
- 2017-03-22 ES ES17712782T patent/ES2861440T5/es active Active
- 2017-03-22 JP JP2018549812A patent/JP6777757B2/ja active Active
- 2017-03-22 WO PCT/EP2017/056851 patent/WO2017162755A1/en not_active Ceased
- 2017-03-22 MY MYPI2018703273A patent/MY187655A/en unknown
- 2017-03-22 KR KR1020187029952A patent/KR102246699B1/ko not_active Expired - Fee Related
- 2017-03-22 ES ES20210821T patent/ES2951136T3/es active Active
- 2017-03-22 EP EP20210821.3A patent/EP3839513B1/en active Active
- 2017-03-22 AU AU2017238442A patent/AU2017238442A1/en not_active Abandoned
- 2017-03-22 SG SG11201807991QA patent/SG11201807991QA/en unknown
- 2017-03-22 EP EP23177260.9A patent/EP4270007A3/en not_active Withdrawn
- 2017-03-22 US US16/087,060 patent/US20200363418A1/en not_active Abandoned
- 2017-03-22 CN CN201780031827.0A patent/CN109313192B/zh not_active Expired - Fee Related
- 2017-03-22 KR KR1020217012412A patent/KR102369544B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2861440T3 (es) | 2021-10-06 |
| EP4270007A3 (en) | 2023-12-20 |
| KR102369544B1 (ko) | 2022-03-03 |
| WO2017162755A1 (en) | 2017-09-28 |
| EP3839513B1 (en) | 2023-06-14 |
| EP3433616B2 (en) | 2024-07-24 |
| KR102246699B1 (ko) | 2021-05-04 |
| EP3433616A1 (en) | 2019-01-30 |
| KR20190013707A (ko) | 2019-02-11 |
| KR20210049954A (ko) | 2021-05-06 |
| US20200363418A1 (en) | 2020-11-19 |
| AU2017238442A1 (en) | 2018-10-11 |
| GB201604806D0 (en) | 2016-05-04 |
| CA3018428C (en) | 2024-03-19 |
| EP4270007A2 (en) | 2023-11-01 |
| EP3433616B1 (en) | 2020-12-30 |
| JP2019510974A (ja) | 2019-04-18 |
| CA3018428A1 (en) | 2017-09-28 |
| EP3839513A1 (en) | 2021-06-23 |
| EP3839513C0 (en) | 2023-06-14 |
| ES2951136T3 (es) | 2023-10-18 |
| JP6777757B2 (ja) | 2020-10-28 |
| MY187655A (en) | 2021-10-07 |
| CN109313192B (zh) | 2022-07-26 |
| ES2861440T5 (en) | 2025-02-05 |
| CN109313192A (zh) | 2019-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201910019PA (en) | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201808192RA (en) | Non-invasive diagnostic of non-alcoholic steatohepatitis | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201804856VA (en) | C-terminal lysine conjugated immunoglobulins | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201807991QA (en) | Use of nucleosome-transcription factor complexes for cancer detection | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same |